Serotonin and Its Receptor as a New Antioxidant Therapeutic Target for Diabetic Kidney Disease

Diabetic kidney disease (dkd) is a widespread chronic microvascular complication of diabetes mellitus (dm),affects almost 30-50% of patients,and represents a leading cause of death of dm. serotonin or 5-hydroxytryptamine (5-ht) is a multifunctional bioamine that has crucial roles in many physiological pathways. recently,emerging evidence from experimental and clinical studies has demonstrated that 5-ht is involved in the pathogenesis of diabetic vascular complications. the 5-ht receptor (5-htr) antagonists exert renoprotective effects by suppressing oxidative stress,suggesting that 5-htr can be used as a potential target for treating dkd. in this review,therefore,we summarize the published information available for the involvement of 5-ht and 5-htr antagonists in the pathogenesis of various diabetic complications with a particular focus of dkd. we conclude that 5-htr is a potential therapeutic target for treating dkd,as it has been successfully applied in animal models and has currently being investigated in randomized and controlled clinical trials. © 2017 yu yang et al.